Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia
Recent evidence shows that reexpression and upregulation of angiotensin II (ANG II) type 2 (AT2) receptor in adult tissues occur during pathological conditions such as tissue hyperplasia, inflammation, and remodeling. In particular, expression of functional AT2 receptors in the pituitary and their p...
| Publicado: |
2004
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01931849_v286_n549-5_pE786_Suarez http://hdl.handle.net/20.500.12110/paper_01931849_v286_n549-5_pE786_Suarez |
| Aporte de: |
| id |
paper:paper_01931849_v286_n549-5_pE786_Suarez |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_01931849_v286_n549-5_pE786_Suarez2023-06-08T15:20:03Z Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia Calcium signaling Prolactin Reverse transcriptase-polymerase chain reaction Western blot angiotensin 1 receptor antagonist angiotensin 2 receptor angiotensin 2 receptor antagonist diethylstilbestrol estrogen hydroxyprogesterone caproate progesterone prolactin animal experiment animal model animal tissue article controlled study female hyperpituitarism hypophysis nonhuman priority journal prolactin release protein expression rat reverse transcription polymerase chain reaction Western blotting 17-alpha-Hydroxyprogesterone Analysis of Variance Animals Calcium Signaling Diethylstilbestrol Down-Regulation Estrogens, Non-Steroidal Female Hyperplasia Pituitary Diseases Pituitary Gland Prolactin Rats Rats, Sprague-Dawley Receptor, Angiotensin, Type 1 Receptor, Angiotensin, Type 2 RNA, Messenger Up-Regulation Recent evidence shows that reexpression and upregulation of angiotensin II (ANG II) type 2 (AT2) receptor in adult tissues occur during pathological conditions such as tissue hyperplasia, inflammation, and remodeling. In particular, expression of functional AT2 receptors in the pituitary and their physiological significance and regulation have not been described. In this study, we demonstrate that chronic in vivo estrogen treatment, which induces pituitary hyperplasia, enhances local AT2 expression (measured by Western blot and RT-PCR) concomitantly with downregulation of ANG II type 1 (AT1) receptors. In vivo progesterone treatment of estrogen-induced pituitary hyperplasia did not modify either the ANG II receptor subtype expression pattern or octapeptide-induced and AT1-mediated calcium signaling. Nevertheless, an unexpected potentiation of the ANG II prolactin-releasing effect was observed in this group, and this response was sensitive to both AT1 and AT2 receptor antagonists. These data are the first to document that ANG II can act at the pituitary level through the AT2 receptor subtype and that estrogens display a differential regulation of AT1 and AT2 receptors at this level. 2004 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01931849_v286_n549-5_pE786_Suarez http://hdl.handle.net/20.500.12110/paper_01931849_v286_n549-5_pE786_Suarez |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Calcium signaling Prolactin Reverse transcriptase-polymerase chain reaction Western blot angiotensin 1 receptor antagonist angiotensin 2 receptor angiotensin 2 receptor antagonist diethylstilbestrol estrogen hydroxyprogesterone caproate progesterone prolactin animal experiment animal model animal tissue article controlled study female hyperpituitarism hypophysis nonhuman priority journal prolactin release protein expression rat reverse transcription polymerase chain reaction Western blotting 17-alpha-Hydroxyprogesterone Analysis of Variance Animals Calcium Signaling Diethylstilbestrol Down-Regulation Estrogens, Non-Steroidal Female Hyperplasia Pituitary Diseases Pituitary Gland Prolactin Rats Rats, Sprague-Dawley Receptor, Angiotensin, Type 1 Receptor, Angiotensin, Type 2 RNA, Messenger Up-Regulation |
| spellingShingle |
Calcium signaling Prolactin Reverse transcriptase-polymerase chain reaction Western blot angiotensin 1 receptor antagonist angiotensin 2 receptor angiotensin 2 receptor antagonist diethylstilbestrol estrogen hydroxyprogesterone caproate progesterone prolactin animal experiment animal model animal tissue article controlled study female hyperpituitarism hypophysis nonhuman priority journal prolactin release protein expression rat reverse transcription polymerase chain reaction Western blotting 17-alpha-Hydroxyprogesterone Analysis of Variance Animals Calcium Signaling Diethylstilbestrol Down-Regulation Estrogens, Non-Steroidal Female Hyperplasia Pituitary Diseases Pituitary Gland Prolactin Rats Rats, Sprague-Dawley Receptor, Angiotensin, Type 1 Receptor, Angiotensin, Type 2 RNA, Messenger Up-Regulation Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| topic_facet |
Calcium signaling Prolactin Reverse transcriptase-polymerase chain reaction Western blot angiotensin 1 receptor antagonist angiotensin 2 receptor angiotensin 2 receptor antagonist diethylstilbestrol estrogen hydroxyprogesterone caproate progesterone prolactin animal experiment animal model animal tissue article controlled study female hyperpituitarism hypophysis nonhuman priority journal prolactin release protein expression rat reverse transcription polymerase chain reaction Western blotting 17-alpha-Hydroxyprogesterone Analysis of Variance Animals Calcium Signaling Diethylstilbestrol Down-Regulation Estrogens, Non-Steroidal Female Hyperplasia Pituitary Diseases Pituitary Gland Prolactin Rats Rats, Sprague-Dawley Receptor, Angiotensin, Type 1 Receptor, Angiotensin, Type 2 RNA, Messenger Up-Regulation |
| description |
Recent evidence shows that reexpression and upregulation of angiotensin II (ANG II) type 2 (AT2) receptor in adult tissues occur during pathological conditions such as tissue hyperplasia, inflammation, and remodeling. In particular, expression of functional AT2 receptors in the pituitary and their physiological significance and regulation have not been described. In this study, we demonstrate that chronic in vivo estrogen treatment, which induces pituitary hyperplasia, enhances local AT2 expression (measured by Western blot and RT-PCR) concomitantly with downregulation of ANG II type 1 (AT1) receptors. In vivo progesterone treatment of estrogen-induced pituitary hyperplasia did not modify either the ANG II receptor subtype expression pattern or octapeptide-induced and AT1-mediated calcium signaling. Nevertheless, an unexpected potentiation of the ANG II prolactin-releasing effect was observed in this group, and this response was sensitive to both AT1 and AT2 receptor antagonists. These data are the first to document that ANG II can act at the pituitary level through the AT2 receptor subtype and that estrogens display a differential regulation of AT1 and AT2 receptors at this level. |
| title |
Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| title_short |
Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| title_full |
Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| title_fullStr |
Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| title_full_unstemmed |
Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| title_sort |
upregulation of angiotensin ii type 2 receptor expression in estrogen-induced pituitary hyperplasia |
| publishDate |
2004 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01931849_v286_n549-5_pE786_Suarez http://hdl.handle.net/20.500.12110/paper_01931849_v286_n549-5_pE786_Suarez |
| _version_ |
1768543321596100608 |